J&J: presents results on nipocalimab

(CercleFinance.com) - The molecular properties of nipocalimab in the treatment of generalized myasthenia gravis will be presented at the 2024 annual meeting of the American Academy of Neurology.


Analysis of clinical and non-clinical studies confirms the potential of the investigational treatment for a rapid, profound and long-lasting decrease in immunoglobulin G (IgG) says the group.

These data show that nipocalimab is a potential best-in-class blocker of FcRn, with unique features including high binding affinity and specificity for the immunoglobulin G (IgG) binding site of FcRn.

The new data provides further evidence of nipocalimab's potential to deliver optimized therapeutic outcomes for autoantibody-induced neurological diseases such as von Willebrand disease, J&J said.

It added that there remains a significant unmet need for more effective therapies capable of providing sustained disease control in the case of gMG.


Copyright (c) 2024 CercleFinance.com. All rights reserved.